Home Newsfeeds Morgan Stanley Maintains Equal-Weight on SolarEdge Technologies, Raises Price Target to $352

Morgan Stanley Maintains Equal-Weight on SolarEdge Technologies, Raises Price Target to $352

Morgan Stanley analyst Stephen Byrd maintains SolarEdge Technologies (NASDAQ:SEDG) with a Equal-Weight and raises the price target from $316 to $352.

byBenzinga Newsdesk

August 18, 2022

1 minute read

Morgan Stanley analyst Stephen Byrd maintains SolarEdge Technologies (NASDAQ:SEDG) with a Equal-Weight and raises the price target from $316 to $352.

News

Supermicro Extends AI And GPU Rack Scale Solutions With Support For AMD Instinct MI300 Series Accelerators

By Benzinga Newsdesk

December 6, 4:02 PM

New 8-GPU Systems Powered by AMD Instinct™ MI300X Accelerators Are Now Available with Breakthrough AI and HPC Performance for Large Scale AI Training and LLM DeploymentsSAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/

AMD

Analyst Ratings

Where Knight-Swift Stands With Analysts

By Benzinga Insights

October 2, 3:00 PM

Over the past 3 months, 14 analysts have published their opinion on Knight-Swift (NYSE:KNX) stock. These analysts are…

KNX

Ford Q2 Earnings Highlights: Revenue Beat, EPS Beat, EV Revenue Up 39% Year-Over-Year, Production Updates And More

By Chris Katje

July 27, 4:42 PM

Big Three automaker Ford Motor (NYSE: F) reported second-quarter financial results after market close Thursday. Here are the key highlights.

SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome

By Vuk Zdinjak

July 8, 9:58 AM

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S.

SPRC

Morgan Stanley Maintains Equal-Weight on SolarEdge Technologies, Raises Price Target to $352

Related Posts

Supermicro Extends AI And GPU Rack Scale Solutions With Support For AMD Instinct MI300 Series Accelerators

Where Knight-Swift Stands With Analysts

Ford Q2 Earnings Highlights: Revenue Beat, EPS Beat, EV Revenue Up 39% Year-Over-Year, Production Updates And More

SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome